The AI inference layer for global healthcare.
Hospitals don't need another software package. They need an AI-native operating system that grows with the future of medicine. That's what we're building.
Request investor deckA massive, underserved market.
$65B+
Global Hospital Management Systems market by 2030 (CAGR 12.4%)
$20B+
India healthcare IT market by 2028
80%+
Indian hospitals still running on paper or legacy systems
40+
Modules in a single unified platform — vs. fragmented competitors
Why Diagnotica wins.
AI-Native Architecture
Not a bolt-on. AI inference is the core — every module feeds into and benefits from the AI layer.
Platform Density
40+ modules in one platform vs. competitors who stitch together 5–6 vendors. Single data model, zero silos.
Multi-Market Design
Built for Indian hospitals but architected for US/EU compliance from day one — HIPAA, GDPR, ABDM-ready.
Cost-Effective
AI-powered HMS at a fraction of Epic/Oracle pricing — making enterprise-grade AI accessible to L3–L5 hospitals.
Regulatory Depth
10+ compliance certifications built into the product — not afterthoughts bolted on post-launch.
Speed of Deployment
8–12 week go-live vs. industry average of 12–18 months. Modular architecture enables phased rollouts.
Platform at a glance.
40+
Production-ready modules
9
AI agents in production
75+
API routers in the gateway
10+
Compliance certifications
L3–L5
Hospital tiers served
4
Product verticals (HMS, AI, Patient App, Genomics)
Investment Thesis
- Healthcare IT is undergoing a generational shift from legacy systems to AI-native platforms.
- India alone has 69,000+ hospitals — fewer than 15% use modern software. The greenfield opportunity is enormous.
- Diagnotica's architecture serves both emerging markets (India, ME, SEA) and premium markets (US, EU) with the same core product.
- AI inference as a platform creates network effects — more data makes the AI better, which attracts more hospitals.
- Compliance-first design (10+ certifications) creates a structural barrier to entry for lightweight competitors.
- Genomics and longevity science (eNatural) opens an entirely new revenue vertical within the same patient relationship.
Let's build the future of healthcare together.
If our vision resonates, we'd love to share our detailed deck and financials.